Study guide

14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order

Key Takeaways Explain This Topic AI

Breast: bilateral breast cancer is multiple primaries (M7), a subsequent tumor in the same breast after more than five disease-free years is a new primary (M5), and carcinoma NST/duct plus lobular tumors in one breast are a single primary (M10).

Colon: FAP (or more than 100 polyps) with carcinoma is a single primary (M3), colon and rectum tumors are multiple primaries (M4), and tumors in different colon segments are multiple primaries (M9).

Colon anastomotic tumors are multiple primaries if they arise in the mucosa, are a NOS and its subtype, or occur more than 36 months after resection (M7); otherwise they are a single primary (M8).

Lung: a new tumor after more than three disease-free years is a new primary (M4), neuroendocrine plus non-small cell tumors are multiple primaries (M5), and simultaneous multiple tumors in one or both lungs are a single primary unless histologies differ (M9).

Lung M11 makes a single tumor in each lung two primaries unless there is proof one is metastatic; across all three modules, an invasive tumor more than 60 days after an in situ tumor is a new primary.

Last updated: September 2026

How to read these tables

Each table lists the Multiple Tumors rules for a module, in order. The Unknown and Single Tumor sections come first: a single tumor is always one primary, and "unknown if single or multiple" gives one primary. Remember the hierarchy: the first rule that applies decides the case.

Breast (C500–C509)

  • Rule Outcome When
  • M4 Multiple Separate tumors in sites that differ at the 2nd or 3rd character (for example, C50 and C18)

M5 Multiple Subsequent tumor in the same breast after the patient was clinically disease-free for more than 5 years since diagnosis or last recurrence. A primary in the other breast does not restart the clock

M6 Single Inflammatory carcinoma in multiple quadrants of one breast, or in both breasts

M7 Multiple Bilateral breast cancer (right and left). A physician's phrase "bilateral breast cancer" does not make it one primary. Histologies may be the same or different

  • M8 Single Paget disease with synchronous underlying carcinoma NST (duct) or its subtypes
  • M9 Multiple Paget disease with an underlying tumor that is not duct (for example, lobular)
  • M10 Single Multiple tumors of carcinoma NST/duct and lobular (mixed 8522, or one duct and one lobular)

M11 Single Ductal carcinoma after a combination code in the same breast (for example, DCIS after DCIS plus LCIS 8522/2)

  • M12 Multiple Tumors that are two or more different subtypes/variants (column 3, Table 3). Timing is irrelevant
  • M13 Single Synchronous tumors on the same row of Table 3 (same code, synonym, or NOS plus its subtype)
  • M14 Multiple Tumors on different rows of Table 3, or a Table 2 combination code plus a Table 3 code

M15 Single (the invasive) In situ diagnosed after invasive in the same breast. Record the in situ as a recurrence

  • M16 Single (the invasive) Invasive 60 days or less after in situ in the same breast
  • M17 Multiple Invasive more than 60 days after in situ in the same breast
  • M18 Single None of the above

Site coding reminders: multiple tumors in different quadrants of the same breast that are a single primary are coded C509 , not C508. C508 is for a single tumor overlapping quadrants, or at 12, 3, 6 or 9 o'clock.

Worked case: a right breast lumpectomy in 2019 shows invasive carcinoma NST. In 2026 a new invasive carcinoma NST appears in the right breast after continuous disease-free follow-up. Seven years without recurrence meets M5 , so the 2026 tumor is a new primary. If the tumor had appeared in the left breast in 2026, M7 would make it a new primary regardless of timing.

Colon, rectosigmoid and rectum (C180–C189, C199, C209)

Rule Outcome When

M3 Single Adenocarcinoma (in situ or invasive) in at least one polyp and a clinical diagnosis of FAP , more than 100 polyps, or polyps "carpeting" the bowel. Site: C189 if more than one colon segment; C199 if colon plus rectosigmoid or rectum; C260 if colon plus small intestine. Multiple polyps alone are not FAP

M4 Multiple Sites differ at the 2nd or 3rd character, for example colon C18 and rectum C209 (not for FAP, and not for a single tumor overlapping colon and rectum)

  • M5 Multiple Two or more different subtypes/variants (column 3, Table 1). Timing irrelevant
  • M6 Multiple Different rows in Table 1. Timing irrelevant

M7 Multiple Subsequent tumor at the anastomosis when it is a NOS and a subtype of that NOS, or occurs more than 36 months after resection (24 months for pre-2022 cases), or arises in the mucosa

M8 Single Anastomotic tumor 36 months or less after resection, or arising in the wall or surrounding tissue without mucosal involvement, or documented as anastomotic recurrence. A rectal stump is an anastomotic site

M9 Multiple Separate tumors in sites that differ at the 4th character , meaning different colon segments (for example, sigmoid C187 and descending C186). Not used for C189

M10 Multiple Subsequent tumor after being clinically disease-free for more than one year since diagnosis or last recurrence. Follow the rule even if the physician calls it a recurrence

  • M11 Single Synchronous tumors on the same row of Table 1
  • M12 Single (the invasive) In situ after invasive. Record the in situ as a recurrence

M13 Single (the invasive) Invasive 60 days or less after in situ. Change the original behavior to /3 and keep the original date of diagnosis

  • M14 Multiple Invasive more than 60 days after in situ, even if the physician says recurrence
  • M15 Single None of the above. Example: in situ and invasive adenocarcinoma in the same segment

Worked cases:

Synchronous adenocarcinomas in the cecum (C180) and the sigmoid (C187), no FAP: M9 applies, giving two primaries .

A patient with FAP has adenocarcinomas in polyps of the ascending and sigmoid colon: M3 applies, giving one primary, C189 .

A hemicolectomy was done in January 2024, and adenocarcinoma arises in the anastomotic mucosa in November 2025: M7 applies, giving a new primary , even though it is within 36 months.

Lung (C340–C343, C348, C349)

  • Rule Outcome When
  • M3 Multiple Sites differ at the 2nd or 3rd character

M4 Multiple Subsequent tumor after being clinically disease-free for more than 3 years since diagnosis or last recurrence

M5 Multiple At least one neuroendocrine carcinoma or tumor (or subtype) and another tumor that is a non-small cell carcinoma subtype

  • M6 Multiple Two or more different subtypes/variants (column 3, Table 3). Timing irrelevant
  • M7 Single Synchronous tumors in the same lung on the same row of Table 3
  • M8 Multiple Different rows in Table 3, or a Table 2 combination code plus a Table 3 code

M9 Single Simultaneous multiple tumors in both lungs (several on each side), in the same lung, or a single tumor in one lung with multiple tumors in the other. Exception: not if pathology proves different histologies, or if the attending physician, oncologist or pulmonologist states unequivocally that they are different primaries. Ambiguous terms such as "probable" do not count

M10 Single (the invasive) In situ after invasive in the same lung

M11 Multiple A single tumor in each lung , unless there is proof that one is metastatic (pathology comparison, or an unequivocal physician statement)

M12 Single (the invasive) Invasive 60 days or less after in situ in the same lung

M13 Multiple Invasive more than 60 days after in situ in the same lung, even if the physician calls it recurrence

M14 Single None of the above

Worked cases:

CT shows three adenocarcinoma nodules in the right lung and two in the left, all diagnosed together, and no physician calls them separate primaries: M9 applies, giving one primary . Laterality is 4 if the side of origin is unknown.

A 2.1 cm right upper lobe adenocarcinoma and a 1.4 cm left lower lobe adenocarcinoma are found at the same time, and nothing proves either is metastatic: M11 applies, giving two primaries .

A small cell carcinoma is found two years after a resected adenocarcinoma: M5 applies, giving two primaries . The M4 timing rule is not needed.

Timing summary

  • Module New primary if disease-free for more than
  • Colon, rectosigmoid, rectum 1 year (M10)
  • Lung 3 years (M4)
  • Breast, same breast 5 years (M5)
  • In situ followed by invasive (all three modules) 60 days

Loading diagram... Key breast decisions in rule order